Adjuvant Trials

1. Double Blind Placebo Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC
   Identifier                         NCT02273375        
This study is currently active, not recruiting. 
The purpose of this study is to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy) for lung cancer.         
Cross Cancer Institute, Edmonton
Tom Baker Cancer Centre, Calgary

Newfoundland & Labrador
Dr H Bliss Murphy Cancer Centre, St John's
Nova Scotia
QE II Health Sciences Centre, Halifax

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton
Cancer Centre of Southeastern Ontario at Kingston, Kingston
Lakeridge Health, Oshawa
Ottawa Hospital Research Institute, Ottawa
Algoma District Cancer Program, Sault Ste Marie
Niagara Health System, St Catherines
Health Sciences North, Sudbury
Thunder Bay Regional Health Science Centre, Thunder Bay 
Mount Sinai Hospital, Toronto, ON
Princess Margaret Hospital, University Health Network, Toronto
McGill University Oncology Department, Montreal

Allan Blair  Cancer Centre, Regina
Saskatoon Cancer Centre, Saskatoon 

2. Study Of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects with Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected NSCLC (CANOPY-A)     
            Identifier                                NCT03447769  

This study is currently recruiting.
The primary purpose of the study is to compare the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II -IIIA and the subset of IIIB (T>5cm N2 disease) completely resected (R0) non-small cell lung cancer (NSCLC).

New Brunswick 



3. AZD9291 Versus Placebo in Patients with Stage IB-IIIA Non-small Cell Lung Carcinoma, Folowing Complete Tumour Resection With or Without Adjuvant Chemotherapy (ADAURA) 
   Identifier                         NCT02511106         

This study is active but not currently recruiting. 

A Phase III, Double-blind, Randomized, Placebo-controlled Multi-centre, Study to Assess the Efficacy and Safety of AZD9291 Versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy (ADAURA)

New Brunswick